Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Metrics to compare | SPRC | Peers Peers - average of corresponding metrics from companies closely matching SPRC: MOREPENLAB, KOPRAN, 540694, ACCENTMIC, 524790 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRCPeersSector |
---|---|---|---|---|
P/E Ratio | −15.2x | 26.3x | −0.5x | |
PEG Ratio | −0.66 | 0.23 | 0.00 | |
Price/Book | −21.0x | 3.2x | 2.6x | |
Price / LTM Sales | 70.4x | 2.2x | 3.3x | |
Upside (Analyst Target) | - | 12.5% | 38.9% | |
Fair Value Upside | Unlock | 1.8% | 5.4% | Unlock |